Argos Therapeutics Inc. (ARGS) Downgraded by Zacks Investment Research
Argos Therapeutics Inc. (NASDAQ:ARGS) was downgraded by Zacks Investment Research from a “buy” rating to a “hold” rating in a research note issued to investors on Tuesday.
According to Zacks, “Argos Therapeutics is a biopharmaceutical company which focused on the development and commercialization of fully personalized immunotherapies for the treatment of cancer and infectious diseases based on its Arcelis (TM) technology platform. Argos Therapeutics is based in Durham, United States. “
Several other equities analysts have also commented on the stock. FBR & Co dropped their price target on shares of Argos Therapeutics from $14.00 to $13.00 and set an “outperform” rating for the company in a research report on Thursday, August 11th. Piper Jaffray Cos. reaffirmed an “overweight” rating and set a $11.00 price target on shares of Argos Therapeutics in a research report on Monday, June 20th. Finally, Needham & Company LLC reaffirmed a “buy” rating and set a $11.00 price target on shares of Argos Therapeutics in a research report on Friday, June 17th. One analyst has rated the stock with a hold rating and seven have issued a buy rating to the stock. The company presently has an average rating of “Buy” and a consensus target price of $11.50.
This story is the sole property of American Banking News and it was originally published by American Banking News. If you are reading this story on another website, that means this article was illegally copied and re-published to this website in violation of U.S. and International copyright law. The original version of this article is available at http://www.americanbankingnews.com/2016/10/11/argos-therapeutics-inc-args-downgraded-by-zacks-investment-research-2.html
Shares of Argos Therapeutics (NASDAQ:ARGS) traded up 0.82% during midday trading on Tuesday, hitting $4.89. 101,909 shares of the stock were exchanged. The firm has a 50 day moving average of $4.87 and a 200 day moving average of $5.92. The firm’s market cap is $201.45 million. Argos Therapeutics has a 12-month low of $1.61 and a 12-month high of $13.97.
Argos Therapeutics (NASDAQ:ARGS) last posted its quarterly earnings data on Wednesday, August 10th. The biopharmaceutical company reported ($0.48) earnings per share for the quarter, missing analysts’ consensus estimates of ($0.43) by $0.05. Equities analysts forecast that Argos Therapeutics will post ($1.56) EPS for the current fiscal year.
In other Argos Therapeutics news, major shareholder International S. Pharmstandard acquired 75,474 shares of the company’s stock in a transaction dated Monday, August 22nd. The stock was bought at an average price of $4.24 per share, with a total value of $320,009.76. The transaction was disclosed in a filing with the Securities & Exchange Commission, which can be accessed through this link. Also, major shareholder International S. Pharmstandard acquired 16,977 shares of the company’s stock in a transaction dated Thursday, September 1st. The stock was acquired at an average cost of $4.78 per share, with a total value of $81,150.06. The disclosure for this purchase can be found here. 61.64% of the stock is currently owned by insiders.
Several large investors have recently added to or reduced their stakes in the company. BlackRock Fund Advisors raised its stake in Argos Therapeutics by 880.1% in the second quarter. BlackRock Fund Advisors now owns 281,679 shares of the biopharmaceutical company’s stock valued at $1,727,000 after buying an additional 252,940 shares during the last quarter. Vanguard Group Inc. raised its stake in Argos Therapeutics by 57.2% in the second quarter. Vanguard Group Inc. now owns 377,497 shares of the biopharmaceutical company’s stock valued at $2,314,000 after buying an additional 137,390 shares during the last quarter. State Street Corp acquired a new stake in Argos Therapeutics during the second quarter valued at about $741,000. BlackRock Institutional Trust Company N.A. acquired a new stake in Argos Therapeutics during the second quarter valued at about $363,000. Finally, Oxford Asset Management acquired a new stake in Argos Therapeutics during the second quarter valued at about $353,000. 11.05% of the stock is owned by institutional investors.
Argos Therapeutics Company Profile
Argos Therapeutics, Inc (Argos) is an immuno-oncology company. The Company is focused on the development and commercialization of individualized immunotherapies for the treatment of cancer and infectious diseases based on its technology platform called Arcelis. The Company’s Arcelis technology platform utilizes biological components from a patient’s own cancer cells or virus to generate individualized immunotherapies.
For more information about research offerings from Zacks Investment Research, visit Zacks.com
Receive News & Ratings for Argos Therapeutics Inc. Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Argos Therapeutics Inc. and related companies with MarketBeat.com's FREE daily email newsletter.